Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
Open accessThe DOI matches its Crossref record; 172 of the 172 references it cites were found in a registry or an index.
Abstract
Cancer causes the second-highest rate of death world-wide. A major shortcoming inherent in most of anticancer drugs is their lack of tumor selectivity. Nanodrugs for cancer therapy administered intravenously escape renal clearance, are unable to penetrate through tight endothelial junctions of normal blood vessels and remain at a high level in plasma. Over time, the concentration of nanodrugs builds up in tumors due to the EPR effect, reaching several times higher than that of plasma due to the lack of lymphatic drainage. This review will address in detail the progress and prospects of tumor-targeting via EPR effect for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 The two phenomena of extravasation and later diffusion and convection of the colloid in the extracellular matrix both result in enhanced permeation and retention of the nanoparticles [32].](https://figures.cochat.ai/paper-figures/887ab73c266443efbb3420cd636da176/recent-advances-in-tumor-targeting-via-epr-effect-for-cancer-treatment-figure-1.jpg)
![Figure 2 Common strategies utilizing the EPR effect [109].](https://figures.cochat.ai/paper-figures/89ba4512a64543b1a593fb62b3bf1725/recent-advances-in-tumor-targeting-via-epr-effect-for-cancer-treatment-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In clinical settings, one of the main challenges for the delivery of macromolecules and nanomedicine to the cancer site is due to the heterogeneity of the EPR effect in solid tumors [20].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“Several studies have demonstrated that only 0.1 to 0.2% of the injected dose is efficient against tumor cells and exhibits significant anticancer effects [20,123,161].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873 · cited 1×
“The rapid tumor growth and improper development of blood vessels in murine tumors result in a much leakier vasculature as compared to human tumors that can lead to misinterpretation of the EPR effect [78].”
BackgroundDoxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792 · cited 1×
“The liposomal doxorubicin extravasated and accumulated intact in tumors with a leaky vasculature [79].”
BackgroundNanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233 · cited 1×
“To date, the FDA has approved many other liposomal formulations such as DaunoXome®, which contains daunorubicin, and Marquibo®, which contains vincristine sulfate for cancer therapy [123] as well as other types of nanoparticle including polymeric micelles containing paclitaxel (Genexol® PM), micelles built with PEG an…”
BackgroundFactors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699 · cited 1×
“The physicochemical properties of any external material for therapeutic or diagnostic purposes are important in drug delivery as they impact the way the host defense mechanisms clear them from the systemic circulation [57,58].”
BackgroundLiposome: classification, preparation, and applications
Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., Samiei, M., Kouhi, M., & Nejati-Koshki, K. (2013) · Nanoscale Research Letters · doi:10.1186/1556-276x-8-102 · Cited by 3,632
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180 · cited 3×
“They also depend on what stage the cancer is and the site it is located at [26,27,39].”
BackgroundNanoparticles in cancer therapy and diagnosis
Brigger, I., Dubernet, C., & Couvreur, P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00044-3 · Cited by 3,039 · cited 1×
“These nanoparticles with a size below 50 nm are mostly used for the detection of brain tumors [140].”
REJMAN, J., OBERLE, V., ZUHORN, I. S., & HOEKSTRA, D. (2004) · Biochemical Journal · doi:10.1042/bj20031253 · Cited by 2,864 · cited 1×
“and spleen, but large enough to avoid kidney clearance [7,8].”
BackgroundBertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Research works printed but not linked: 1
- Dellian, 2000, Vascular permeability in a human tumour xenograft: Molecular charge dependence, Br. J. Cancer, 82, 1513
Cited by
Effects of nanoparticle size, shape, and zeta potential on drug delivery
Öztürk, K., Kaplan, M., & Çalış, S. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124799 · Cited by 449
Nanotechnology in healthcare, and its safety and environmental risks
Ma, X., Tian, Y., Yang, R., Wang, H., Allahou, L. W., Chang, J., Williams, G., Knowles, J. C., & Poma, A. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02901-x · Cited by 332
Strategies to improve the EPR effect: A mechanistic perspective and clinical translation
Ikeda-Imafuku, M., Wang, L. L.-W., Rodrigues, D., Shaha, S., Zhao, Z., & Mitragotri, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.043 · Cited by 330
Bajracharya, R., Song, J. G., Patil, B. R., Lee, S. H., Noh, H.-M., Kim, D.-H., Kim, G.-L., Seo, S.-H., Park, J.-W., Jeong, S. H., et al. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2089296 · Cited by 246
“In comparison to free drugs, nano-DDS have hydrodynamic diameters exceeding the renal clearance threshold and have prolonged circulation in the blood, which leads to extravasation from leaky tumor vessels (Golombek et al., 2018; Subhan et al., 2021).”
BackgroundEnhancement of EPR Effect for Passive Tumor Targeting: Current Status and Future Perspectives
Vagena, I.-A., Malapani, C., Gatou, M.-A., Lagopati, N., & Pavlatou, E. A. (2025) · Applied Sciences · doi:10.3390/app15063189 · Cited by 220
Cancer nanomedicine: a review of nano-therapeutics and challenges ahead
Nirmala, M. J., Kizhuveetil, U., Johnson, A., G, B., Nagarajan, R., & Muthuvijayan, V. (2023) · RSC Advances · doi:10.1039/d2ra07863e · Cited by 206
Chlorin e6: A Promising Photosensitizer in Photo-Based Cancer Nanomedicine
Hak, A., Ali, M. S., Sankaranarayanan, S. A., Shinde, V. R., & Rengan, A. K. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.2c00891 · Cited by 182
An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment
Sharifi, M., Cho, W. C., Ansariesfahani, A., Tarharoudi, R., Malekisarvar, H., Sari, S., Bloukh, S. H., Edis, Z., Amin, M., Gleghorn, J. P., et al. (2022) · Cancers · doi:10.3390/cancers14122868 · Cited by 178
Truong, T. T., Mondal, S., Doan, V. H. M., Tak, S., Choi, J., Oh, H., Nguyen, T. D., Misra, M., Lee, B., & Oh, J. (2024) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2024.103263 · Cited by 185
Applications and challenges of ultra-small particle size nanoparticles in tumor therapy
Xu, J., Song, M., Fang, Z., Zheng, L., Huang, X., & Liu, K. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.12.028 · Cited by 185
Lipid-based nanoparticles as drug delivery carriers for cancer therapy
Waheed, I., Ali, A., Tabassum, H., Khatoon, N., Lai, W.-F., & Zhou, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1296091 · Cited by 169
“This selective accumulation reduces systemic side effects by increasing drug delivery to cancer cells while minimizing exposure to normal tissues, which is very useful in treating cancer (8).”
BackgroundTargeted Delivery Methods for Anticancer Drugs
Veselov, V. V., Nosyrev, A. E., Jicsinszky, L., Alyautdin, R. N., & Cravotto, G. (2022) · Cancers · doi:10.3390/cancers14030622 · Cited by 174
“At the same time, it is important to note that the current understanding of the EPR effect is based on results obtained in animal models, meaning that the results of EPR-effect studies in patients must be collated if delivery systems that fully exploit the EPR effect are to be successfully designed [26].”
ResultEl‐Saadony, M. T., Fang, G., Yan, S., Alkafaas, S. S., Nasharty, M. A. E., Khedr, S. A., Hussien, A. M., Ghosh, S. B., Dladla, M., Elkafas, S. S., et al. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s487188 · Cited by 197
Chen, X., Argandona, S. M., Melle, F., Rampal, N., & Fairen‐Jiménez, D. (2023) · Chem · doi:10.1016/j.chempr.2023.09.016 · Cited by 189
Bio-Inspired Nanomaterials for Micro/Nanodevices: A New Era in Biomedical Applications
Harun‐Ur‐Rashid, M., Jahan, I., Foyez, T., & Imran, A. B. (2023) · Micromachines · doi:10.3390/mi14091786 · Cited by 185
Perspectives for Improving the Tumor Targeting of Nanomedicine via the EPR Effect in Clinical Tumors
Kim, J., Cho, H., Lim, D., Joo, M. K., & Kim, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210082 · Cited by 178
“The targeting delivery ability of nanoparticles is greatly influenced by factors related to the TME, such as the dense ECM, tumor cell density, hypoxia, and IFP (Figure 2) [58,59].”
BackgroundCARBON DOTS: Bioimaging and Anticancer Drug Delivery
Bartkowski, M., Zhou, Y., Mustafa, M. N. A., Eustace, A. J., & Giordani, S. (2024) · Chemistry - A European Journal · doi:10.1002/chem.202303982 · Cited by 156
Recent developments in the use of gold and silver nanoparticles in biomedicine
Pasparakis, G. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1817 · Cited by 141
“…excellent imaging modality as it was possible to trace the tumors by PAT, computerized tomography (CT) X-ray, and magnetic resonance (MR) imaging methods due to the passive accumulation of the NPs by the enhanced permeation and retention (EPR) effect (Rosenblum et al., 2018; Subhan et al., 2021).”
MethodChen, Y., Huang, Y., Li, Q., Luo, Z., Zhang, Z., Huang, H., Sun, J., Zhang, L., Sun, R., Bain, D. J., et al. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01266-2 · Cited by 135
Advances in nanoparticle-mediated cancer therapeutics: Current research and future perspectives
Deivayanai, V. C., Thamarai, P., Karishma, S., Saravanan, A., Yaashikaa, P. R., Vickram, A. S., Hemavathy, R. V., Kumar, R. R., Rishikesavan, S., & Shruthi, S. (2024) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2024.11.002 · Cited by 159
“88 Doxorubicin is administered with polymeric NPs, utilizing a temperature-responsive mechanism for passive targeting of brain tumor cells and cancer inhibition; the same drug is also used with magneto-liposomes to harness magnetic fi elds for cancer treatment.”
Developments in nanotechnology approaches for the treatment of solid tumors
Venturini, J., Chakraborty, A., Baysal, M. A., & Tsimberidou, A. M. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00656-1 · Cited by 130
“From a dimensional standpoint, nanodevices should ideally be kept within the range of 50 to 200 nm, thus both exceeding the 40 kDa threshold (corresponding to ~ 5 nm) for renal clearance and remaining small enough to allow for extravasation [34].”
Khan, M. S., Alqahtani, T., Shmrany, H. A., Gupta, G., Goh, K. W., Sahebkar, A., & Kesharwani, P. (2025) · Biomaterials Advances · doi:10.1016/j.bioadv.2025.214636 · Cited by 141
Ahmadi, F., Taleghani, A. S., Ebrahimnejad, P., Moghaddam, S. P. H., Ebrahimnejad, F., Asare‐Addo, K., & Nokhodchi, A. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122099 · Cited by 125
Biomimetic Metallic Nanostructures for Biomedical Applications, Catalysis, and Beyond
Yaraki, M. T., Nasab, S. Z., Zare, I., Dahri, M., Sadeghi, M. M., Koohi, M., & Tan, Y. N. (2022) · Industrial & Engineering Chemistry Research · doi:10.1021/acs.iecr.2c00285 · Cited by 124
Nano-based drug delivery system for therapeutics: a comprehensive review
Prakash, S. (2023) · Biomedical Physics & Engineering Express · doi:10.1088/2057-1976/acedb2 · Cited by 123
Carbon Dots: Opportunities and Challenges in Cancer Therapy
Bhattacharya, T., Shin, G. H., & Kim, J. T. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15031019 · Cited by 117
“Long-term studies have been conducted on the selective delivery of anticancer medications, such as EPR-based tumor therapy [96], but anticancer drugs are not suitable for clinical use because they are unable to deliver treatment in a targeted manner to the tumor.”
BackgroundPromising biomedical applications using superparamagnetic nanoparticles
Fahim, Y. A., Hasani, I. W., & Ragab, W. M. (2025) · European journal of medical research · doi:10.1186/s40001-025-02696-z · Cited by 106
“However, the EPR effect remains highly controversial, with some studies suggesting it may be overstated or even a fallacy in certain contexts due to tumor heterogeneity, inconsistent vascular permeability, and limited clinical translation in humans compared to preclinical models [58, 59].”
Lipid-Based Nanotechnology: Liposome
Jiang, Y., Li, W., Wang, Z., & Lu, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010034 · Cited by 112
“Thus, FTIR provides invaluable insight into the liposome characterization, contributing significantly to the optimization of liposome-based drug delivery platforms.”
Recent advances in drug delivery systems for targeting brain tumors
Zhao, Y., Yue, P., Peng, Y., Sun, Y., Chen, X., Zhao, Z., & Han, B.-J. (2023) · Drug Delivery · doi:10.1080/10717544.2022.2154409 · Cited by 105
“Nanocarriers preferentially accumulate in tumor through passive targeting due to the leaky vasculature and defective lymphatic drainage (Subhan et al., 2021).”
BackgroundOptical blood-brain-tumor barrier modulation expands therapeutic options for glioblastoma treatment
Cai, Q., Li, X., Xiong, H., Fan, H., Gao, X., Vemireddy, V., Margolis, R., Li, J., Ge, X., Giannotta, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40579-1 · Cited by 102
‘Passive’ nanoparticles for organ-selective systemic delivery: design, mechanism and perspective
Fu, L., Zhang, Y., Farokhzad, R. A., Mendes, B. B., Conde, J., & Shi, J. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00998f · Cited by 106
Nanomaterials Enhanced Sonodynamic Therapy for Multiple Tumor Treatment
Yang, M., Wang, X., Peng, M., Wang, F., Hou, S., Xing, R., & Chen, A. (2025) · Nano-Micro Letters · doi:10.1007/s40820-025-01666-8 · Cited by 112
“Nanocarriers can help deliver sonosensitizers more efficiently at target tumor sites while increasing their sonodynamic effects by enhancing permeability and retention (EPR) effects [81, 82].”
Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis
Subhan, M. A., Parveen, F., Filipczak, N., Yalamarty, S. S. K., & Torchilin, V. P. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030389 · Cited by 98
“2% of the injected dose is efficient against tumor cells and exhibits significant anticancer effects [20,123,161].”
BackgroundSelf-citationNanoparticle-enhanced drug delivery systems: An up-to-date review
Chenxi, Z., Hemmat, A., Thi, N., & Afrand, M. (2025) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2025.126999 · Cited by 104
Palanikumar, L., Kalmouni, M., Houhou, T., Abdullah, O., Ali, L., Pasricha, R., Straubinger, R., Thomas, S. A., Afzal, A. J., Barrera, F. N., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c04564 · Cited by 90
Nanomaterials in anticancer applications and their mechanism of action - A review
Das, C. G. A., Kumar, V. G., Dhas, T. S., Karthick, V., & Kumar, C. M. V. (2022) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2022.102613 · Cited by 92
Dendrimers: Advancements and Potential Applications in Cancer Diagnosis and Treatment—An Overview
Crintea, A., Motofelea, A. C., Şovrea, A. S., Constantin, A.-M., Crivii, C. B., Carpa, R., & Duţu, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051406 · Cited by 88
Photonic and magnetic materials for on-demand local drug delivery
Armenia, I., Cuestas-Ayllón, C., Torres‐Herrero, B., Bussolari, F., Alfranca, G., Grazú, V., & de la Fuente, J. M. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114584 · Cited by 84
Kawish, S. M., Sharma, S., Gupta, P., Ahmad, F. J., Iqbal, M., Alshabrmi, F. M., Anwer, M. K., Fathi‐karkan, S., Rahdar, A., & Aboudzadeh, M. A. (2024) · Particle & Particle Systems Characterization · doi:10.1002/ppsc.202400049 · Cited by 87
Emerging nanotherapeutics for facilitating photodynamic therapy
Li, S., Yang, F., Wang, Y., Du, T., & Hou, X. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.138621 · Cited by 85
Emerging Applications of Nanoparticles in the Diagnosis and Treatment of Breast Cancer
Oehler, J. B., Rajapaksha, W., & Albrecht, H. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14070723 · Cited by 90
“To address this, techniques such as size modulation, surface charge optimization, and shape engineering are being explored to maximize the therapeutic efficacy of passively targeted nanoparticles [43,54,55].”
BackgroundMethodInfluentialThroat, S., & Bhattacharya, S. (2024) · Advances in Polymer Technology · doi:10.1155/2024/1444990 · Cited by 80
Ruthenium-based antitumor drugs and delivery systems from monotherapy to combination therapy
Lu, Y., Zhu, D., Le, Q., Wang, Y., & Wang, W. (2022) · Nanoscale · doi:10.1039/d2nr02994d · Cited by 76
Smart Nanotherapeutics and Lung Cancer
Doroudian, M., Azhdari, M. H., Goodarzi, N., O’Sullivan, D., & Donnelly, S. C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111972 · Cited by 75
“The surface charge of the NPs is another factor that determines its durability in blood circulation and reduces their removal over the reticuloendothelial system (RES) [33,34].”
BackgroundAdvances with Lipid-Based Nanosystems for siRNA Delivery to Breast Cancers
Subhan, M. A., Filipczak, N., & Torchilin, V. P. (2023) · Pharmaceuticals · doi:10.3390/ph16070970 · Cited by 75
“PEGylation can increase the stability of nanoparticles in biological fluids and reduce aggregation during storage and during in vivo application [85].”
BackgroundSelf-citationNanocarriers for Drug Delivery: An Overview with Emphasis on Vitamin D and K Transportation
Crintea, A., Duţu, A., Şovrea, A. S., Constantin, A.-M., Samaşcă, G., Masalar, A. L., Ifju, B., Linga, E., Neamți, L., Tranca, R. A., et al. (2022) · Nanomaterials · doi:10.3390/nano12081376 · Cited by 73
Gawali, P., Saraswat, A. L., Bhide, S., Gupta, S., & Patel, K. R. (2023) · Nanomedicine · doi:10.2217/nnm-2022-0257 · Cited by 75
Ikeda-Imafuku, M., Gao, Y., Shaha, S., Wang, L., Park, K. S., Nakajima, M., Adebowale, O., & Mitragotri, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.007 · Cited by 68
Mohamed, R. A., Ali, S. M., Ahmed, I. S., Rawas‐Qalaji, M., & Hussain, Z. (2025) · Biomaterials Science · doi:10.1039/d5bm01176k · Cited by 80
Research Status of Dendrimer Micelles in Tumor Therapy for Drug Delivery
Wang, X., Zhang, M., Li, Y., Cong, H., Yu, B., & Shen, Y. (2023) · Small · doi:10.1002/smll.202304006 · Cited by 64
Novel drug delivery systems: Insight into self-powered and nano-enabled drug delivery systems
Ewii, U. E., Onugwu, A. L., Nwokpor, V. C., Akpaso, I.-A., Ogbulie, T. E., Aharanwa, B., Chijioke, C., Verla, N., Iheme, C. I., Ujowundu, C. O., et al. (2024) · Nano TransMed · doi:10.1016/j.ntm.2024.100042 · Cited by 68
Lysosomal nanotoxicity: Impact of nanomedicines on lysosomal function
Uzhytchak, M., Smolková, B., Lunová, M., Frtús, A., Jirsa, M., Dejneka, A., & Lunov, O. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114828 · Cited by 65
Emergence of magnetic nanoparticles in photothermal and ferroptotic therapies
de Walle, A. V., Figuerola, A., Espinosa, A., Abou‐Hassan, A., Estrader, M., & Wilhelm, C. (2023) · Materials Horizons · doi:10.1039/d3mh00831b · Cited by 64
Nanoparticle-Based Delivery Strategies for Combating Drug Resistance in Cancer Therapeutics
Park, S., Lu, G., Zheng, Y., Davison, E. K., & Li, Y. (2025) · Cancers · doi:10.3390/cancers17162628 · Cited by 69
Stimuli-responsive hydrogel based on natural polymers for breast cancer
Asadi, K., Samiraninezhad, N., Akbarizadeh, A. R., Amini, A., & Gholami, A. (2024) · Frontiers in Chemistry · doi:10.3389/fchem.2024.1325204 · Cited by 60
“Furthermore, tumor temperatures increase (37.17 ° C – 41.44 ° C) due to raised microvessel density and blood fl ow rate (Subhan et al., 2021).”
BackgroundInfluentialJayoush, A. R. A., Haider, M. A., Khan, S. A., & Hussain, Z. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.142486 · Cited by 73
Li, Y., Ke, J., Jia, H., Ren, J., Wang, L., Zhang, Z., & Wang, C. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113131 · Cited by 57
Pegoraro, C., Domingo-Ortí, I., Conejos‐Sánchez, I., & Vicent, M. J. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115195 · Cited by 58
Craft of Co-encapsulation in Nanomedicine: A Struggle To Achieve Synergy through Reciprocity
Bhattacharjee, S. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00033 · Cited by 54
Ahmed, M. M., Anwer, M. K., Fatima, F., Aldawsari, M. F., Alalaiwe, A. S., Alali, A. S., Alharthi, A. I., & Kalam, M. A. (2022) · Polymers · doi:10.3390/polym14122459 · Cited by 53
“According to studies, nanoparticles with a size range of 40 to 400 nm are appropriate for ensuring long circulation duration and increased accumulation of drug in tum rs with limited renal lear nce [38,39].”
BackgroundAwad, N. S., Salkho, N. M., Abuwatfa, W. H., Paul, V., AlSawaftah, N., & Husseini, G. A. (2023) · OpenNano · doi:10.1016/j.onano.2023.100136 · Cited by 52
Wang, C., Sun, X., Feng, L., & Liu, Z. (2024) · BMEMat · doi:10.1002/bmm2.12083 · Cited by 52
Overcoming Cancer Drug Resistance with Nanoparticle Strategies for Key Protein Inhibition
Yoo, H., Kim, Y., Kim, J., Cho, H., & Kim, K. (2024) · Molecules · doi:10.3390/molecules29173994 · Cited by 54
“These pathophysiological factors are crucial considerations in developing personalized and improved nanodrug treatments using the EPR effect [35,39].”
BackgroundThe Role of in silico Research in Developing Nanoparticle-Based Therapeutics
Jayasinghe, M. K., Lee, C. Y., Tran, T., Tan, R., Chew, S. M., Yeo, B. Z. J., Loh, W. X., Pirisinu, M., & Le, M. T. N. (2022) · Frontiers in Digital Health · doi:10.3389/fdgth.2022.838590 · Cited by 57
“However, even these factors together are insufficient to precisely predict the effect of the EPR effect, as noted by Subhan et al. (99), who reported that there are other parameters that might contribute to the EPR effect on NP extravasation, which are not yet known.”
BackgroundResearch Status and Prospect of Non-Viral Vectors Based on siRNA: A Review
Tong, L., Liu, D., Cao, Z., Zheng, N., Mao, C., Liu, S., He, L., & Liu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043375 · Cited by 54
Nanomedicines: Emerging Platforms in Smart Chemotherapy Treatment—A Recent Review
Arafat, M., Sakkal, M., Beiram, R., & Aburuz, S. (2024) · Pharmaceuticals · doi:10.3390/ph17030315 · Cited by 56
“Moreover, the EPR effect can vary significantly within and between tumors, even within the same patient [161,162].”
BackgroundNIR-II Fluorescent Probes for Fluorescence-Imaging-Guided Tumor Surgery
Ullah, Z., Roy, S., Gu, J., Soe, S. K., Jin, J. G., & Guo, B. (2024) · Biosensors · doi:10.3390/bios14060282 · Cited by 55
“Building upon this understanding, these tumor-targeting dyes have been employed to confer tumor-targeting capabilities to other imaging agents through covalent conjugation while retaining the integrity of the meso-Cl [35].”
BackgroundUltrasmall-in-Nano: Why Size Matters
Mellor, R. D., & Uchegbu, I. F. (2022) · Nanomaterials · doi:10.3390/nano12142476 · Cited by 51
“Nanoparticles need to fall within a particular size rage (40–400 nm [47]) in order to take advantage of the enhanced permeability and retention (EPR) effect.”
BackgroundPolymeric Nanoparticles for Targeted Lung Cancer Treatment: Review and Perspectives
Kapoor, D. U., Gandhi, S. M., Swarn, S., Lal, B., Prajapati, B. G., Khondee, S., Mangmool, S., Singh, S. K., & Chittasupho, C. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091091 · Cited by 53
“[148] Tumor location Location determines local blood flow and vessel permeability; tumors in highly vascularized organs differ from those in low-perfusion or protected areas (e.g., brain).”
Badparvar, F., Marjani, A. P., Salehi, R., & Ramezani, F. (2024) · Scientific Reports · doi:10.1038/s41598-024-57296-4 · Cited by 48
“Therefore, hyperbranched MeO-PEG- b-(NIPAAm-co-PBAE) EPR-based NDDSs have the highest tendency to long circulation time and enhanced tumor accumulation 38 .”
BackgroundX-ray Activated Nanoplatforms for Deep Tissue Photodynamic Therapy
Souris, J. S., Leoni, L., Zhang, H. J., Pan, A., Tanios, E., Tsai, H., Balyasnikova, I. V., Bissonnette, M., & Chen, C. (2023) · Nanomaterials · doi:10.3390/nano13040673 · Cited by 47
Extracellular matrix component-derived nanoparticles for drug delivery and tissue engineering
Hogan, K. J., Perez, M. R., & Mikos, A. G. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.034 · Cited by 49
Nittayacharn, P., Abenojar, E., Cooley, M. B., Berg, F. M., Counil, C., Sojahrood, A. J., Khan, M. S., Yang, C. J., Berndl, E. S. L., Golczak, M., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.028 · Cited by 48
Davodabadi, F., Mirinejad, S., Malik, S., Dhasmana, A., Ulucan‐Karnak, F., Sargazi, S., Sargazi, S., Fathi‐karkan, S., & Rahdar, A. (2024) · Nanoscale · doi:10.1039/d3nr05656b · Cited by 50
Advances in Antitumor Nano-Drug Delivery Systems of 10-Hydroxycamptothecin
Chen, Y., Wang, Z., Wang, X., Su, M., Xu, F., Yang, L., Jia, L., & Zhang, Z. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s377149 · Cited by 46
Li, X., Niu, J., Deng, L., Yu, Y., Zhang, L., Chen, Q., Zhao, J., Wang, B., & Gao, H. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.11.019 · Cited by 45
Hoang, C. N. M., Nguyen, S. H., & Tran, M. T. (2025) · Smart Materials in Medicine · doi:10.1016/j.smaim.2025.07.004 · Cited by 45
Palani, N., Mendonce, K. C., Altaf, R. R. S., Mohan, A., Surya, P., Monisha, P., Radhakrishnan, K., Subramaniyan, V., & Rajadesingu, S. (2025) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2025.2540362 · Cited by 51
Advanced Nano-Carriers for Anti-Tumor Drug Loading
Xiang, J., Zhao, R., Wang, B., Sun, X., Guo, X., Tan, S., & Liu, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.758143 · Cited by 45
“At present, many passive targeting nanoparticles have shown promising therapeutic effects in clinical trials, such as Marqibo, Myocet and lysosomes (47).”
BackgroundAmărandi, R.-M., Ibanescu, A., Carasevici, E., Marin, L. B., & Drăgoi, B. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020308 · Cited by 44
“The enhanced accumulation of these long-circulating carrier systems in tumor cells was associated with the increased leakiness of blood vessels and the reduced lymphatic drainage occurring in tumors, referred to as the enhanced permeability and retention (EPR) effect [46].”
BackgroundAI-driven nanomedicine for cancer theranostics
Tiwari, A., Widodo, Krisnawati, D. I., Chen, C.-Y., & Kuo, T. (2026) · Molecular Cancer · doi:10.1186/s12943-025-02563-9 · Cited by 47
Emerging targeted therapeutic strategies for the treatment of triple-negative breast cancer
Kumari, L., Mishra, L., Patel, P., Sharma, N., Gupta, G. D., & Kurmi, B. D. (2023) · Journal of drug targeting · doi:10.1080/1061186x.2023.2245579 · Cited by 42
“The incapability to discriminate among normal and cancerous tissues, insufficient tumour accumulation, intra-and inter-tumoral as well as inter-individual tumour heterogeneity and inadequate tumour accumulation are some of the significant limitations of passive targeting [45].”
BackgroundRosyidah, A., Kerdtoob, S., Yudhistyra, W. I., & Munfadlila, A. W. (2023) · Gold bulletin · doi:10.1007/s13404-023-00331-5 · Cited by 40
“In humans, not all cancers exhibit leaky vasculature and a correspondingly increased permeability to macromolecules [75].”
BackgroundZhou, W., Zhao, Z., Yu, Z., Hou, Y., Keerthiga, R., & Fu, A. (2022) · Mitochondrion · doi:10.1016/j.mito.2022.04.004 · Cited by 41
Moni, S. S., Moshi, J. M., Matou‐Nasri, S., Alotaibi, S., Hawsawi, Y. M., Elmobark, M. E., Hakami, A., Jeraiby, M., Sulayli, A. A., & Moafa, H. N. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17030296 · Cited by 44
“Despite its limitations, the EPR effect remains a cornerstone of nanomedicine and targeted cancer therapies, offering a way to improve the efficacy and safety of cancer treatments [36–38].”
Micro/Nanosystems for Magnetic Targeted Delivery of Bioagents
Garello, F., Svenskaya, Y. I., Parakhonskiy, B. V., & Filippi, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061132 · Cited by 40
“Site-specific targeting of the payload is provided either passively based on the vascular bursts [172] and enhanced permeability and retention (EPR) effect of pathologic tissue [173,174] or initiated actively via specific ligand attachment [175,176] or exploiting superparamagnetic properties of the system (magnetic ta…”
BackgroundXiao, B., Liu, Y., Chandrasiri, I., Adjei‐Sowah, E., Mereness, J. A., Yan, M., & Benoit, D. S. W. (2023) · Small · doi:10.1002/smll.202305336 · Cited by 42
Sorasitthiyanukarn, F. N., Muangnoi, C., Rojsitthisak, P., & Rojsitthisak, P. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130264 · Cited by 38
Shekhar, S., Chauhan, M., Sonali, Yadav, B., Dutt, R., Hu, L., Muthu, M. S., & Singh, R. P. (2022) · Nanomedicine · doi:10.2217/nnm-2022-0065 · Cited by 39
Meylina, L., Muchtaridi, M., Joni, I. M., Elamin, K. M., & Wathoni, N. (2023) · Polymers · doi:10.3390/polym15041025 · Cited by 37
“Studies have shown that the nanoparticle size range between 40 and 400 nm is suitable for extending the circulation time and increasing drug accumulation in tumors [75].”
BackgroundTargeting nanoparticles to malignant tumors
Sharma, N., Bietar, K., & Stochaj, U. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188703 · Cited by 40
Ahmad, J., Rizwanullah, M., Suthar, T., Albarqi, H. A., Ahmad, M. Z., Vuddanda, P. R., Khan, M. A., & Jain, K. (2022) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2022040686 · Cited by 38
Huang, J., He, J., Wang, J., Li, Y., Xu, Z., Zhang, L., Kang, Y., & Xue, P. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122340 · Cited by 37
Cancer Immunotherapy Elicited by Immunogenic Cell Death Based on Smart Nanomaterials
Yang, M., Zhang, C., Wang, R., Wu, X., Li, H., & Yoon, J. (2023) · Small Methods · doi:10.1002/smtd.202201381 · Cited by 41
Gandhi, S., & Roy, I. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051457 · Cited by 38
“However, the EPR effect, which is based on the higher extravasation of circulating macromolecules in tumor tissues owing to their leaky vasculature, as well as their poor lymphatic drainage, has been found to be more pronounced in small animals than in humans [15].”
BackgroundNanostructures and nanoparticles as medical diagnostic imaging contrast agents: A review
Mhlanga, N., Mphuthi, N. G., van der Walt, H., Nyembe, S., Mokhena, T. C., & Sikhwivhilu, L. M. (2024) · Materials Today Chemistry · doi:10.1016/j.mtchem.2024.102233 · Cited by 48
Rahiman, N. (2025) · Cancer Nanotechnology · doi:10.1186/s12645-025-00314-5 · Cited by 36
“For passive targeting, the EPR effect is involved to gain benefit from the intrinsic features of solid tumors for more accumulation of the liposomes either theranostic or conventional (Subhan et al. 2021).”
Giorgi, E., Binacchi, F., Marotta, C., Cirri, D., Gabbiani, C., & Pratesi, A. (2022) · Molecules · doi:10.3390/molecules28010273 · Cited by 38
“Anti-cancer nanomedicine is associated with finding delivery solutions, such as micelles, liposomes, and nanoparticles, that deliver the drug to tumour cells, mainly by exploiting the EPR effect [64,65].”
BackgroundSamad, M. A., Ahmad, I., Zughaibi, T. A., Suhail, M., Zaidi, S. K., Al-Abbasi, F. A., & Tabrez, S. (2025) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2025.100268 · Cited by 35
Jiang, X., Luo, T., Yang, K., Lee, M. J., Liu, J., Tillman, L., Zhen, W., Weichselbaum, R. R., & Lin, W. (2024) · Science Advances · doi:10.1126/sciadv.ado0082 · Cited by 35
“The tumor vasculature is highly heterogeneous with variable vascular permeability, vascular maturation at the vessel level ( 22 ), extracellular matrix ( 23 ), and interstitial fluid pressure ( 24 ).”
Metadata
- Authors
- Subhan, M. A., Yalamarty, S. S. K., Filipczak, N., Parveen, F., & Torchilin, V. P.
- Affiliations
- Shahjalal University of Science and Technology (BD)
- Northeastern University (US)
- Corresponding author
- Subhan, Md Abdus
- Torchilin, Vladimir P.
- ORCID
- Venue
- Journal of Personalized Medicine
- Publisher
- MDPI AG
- Published
- 2021-06-18
- Volume
- 11
- Issue
- 6
- Pages
- 571
- ISSN
- 2075-4426 (ISSN-L)
- PMC
- PMC8234032
- OpenAlex
- W3174294541
- Semantic Scholar
- 0e274cc5538c8ce64b42706c752e9cd357ce4ede
- Cited by
- 623
- References
- 172
- Citations by year
- 2026: 116 · 2025: 167 · 2024: 148 · 2023: 106 · 2022: 82 · 2021: 4
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Personalized Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
- Keywords
- enhanced permeability and retention effect, tumor targeting, cancer nanomedicine, nanotherapeutics, tumor selectivity, intravenous drug delivery, tumor microenvironment, lymphatic drainage
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.